When we discuss and hear about partners of BRN that are announced as integrating the Akida technology into their offerings, can we safely say that some of these newly announced partners already are part of sub-licensing through Megachips? Or are they working with Renesas to build products?
There seems to be a disconnect between the excitement of such partnerships for us shareholders, whether they are or intend to be Akida IP license holders, whether they use third-party chipmakers to produce their desired products, and the point of which these partners' are in their product development cycles.
Eg. "By partnering with BrainChip and implementing Akida technology into medical and industrial solutions, we are able to deliver innovative solutions at a faster time to market than otherwise possible.”
What is a faster time to market? 6months, 1yr, 2yrs, 5yrs?
As much as BRN cannot break their NDAs and need to be highly discreet, I think some sort of communication as to how advanced some of these development cycles are would be reassuring. It is what I believe affects the issues surrounding the polarities of BRN's market valuation, from one of the potential next big 5, to currently, 'the boy who cried wolf'. It encourages an 'all-or-nothing' approach to investing as a shareholder, and why wonderful contributors such as FF are pilloried and bullied out of the public view, despite their tiresome research.